News and Events

Stay up to date on our current affairs.

Nov 21,
2017
Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access
Nov 16,
2017
Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available
Sep 7,
2017
Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal
Sep 6,
2017
Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services
Aug 31,
2017
Mitsubishi Tanabe Pharma America Statement on Access to RADICAVA™ (edaravone)
Aug 9,
2017
MTPA Perspective Regarding Medicare Coverage
Aug 8,
2017
FIRST FDA-APPROVED TREATMENT FOR ALS IN 22 YEARS NOW AVAILABLE IN U.S.
Aug 1,
2017
MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America
Jul 25,
2017
Mitsubishi Tanabe Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVA™ (Edaravone)
Jun 30,
2017
Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients
May 18,
2017
Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVA™ (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting
May 5,
2017
Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA™ (Edaravone), the First New Treatment Option for ALS in More Than 20 Years
May 5,
2017
RADICAVA™ (Edaravone) Prescribing Information
Apr 20,
2017
Mitsubishi Tanabe Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting
Dec 9,
2016
12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND
Sep 20,
2016
The ALS Association Welcomes Mitsubishi Tanabe Pharma America as National Corporate Sponsor
Aug 30,
2016
FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS
Jun 20,
2016
Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States
Apr 20,
2016
Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting